~~<i id='388F933EF3'><strike id='388F933EF3'><tt id='388F933EF3'><pre id='388F933EF3'></pre></tt></strike></i>~~

Home» knowledge» fashion

fashion

author：explore 2025-10-04 07:53:48 Page View：772

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

A couple billion here, a couple billion there, and pretty soon Eli Lilly hopes it will be talking about real money.

Eli Lilly agreed to purchase Point Biopharma Tuesday morning for $1.4 billion, a 90% premium, adding to its pipeline of cancer drugs. Point is developing cancer drugs that deliver a focused dose of radiation to tumor cells. Data for its lead medicine, for prostate cancer, are expected in the fourth quarter. It is also developing a drug for neuroendocrine tumors.

Point operates a 180,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, and a radiopharmaceutical research and development center in Toronto.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Test for long Covid? Researchers find new clue in blood samples
Next article： Heart attack and stroke risk calculators need revising

focus

DIEP, the 'gold standard' of breast reconstruction, is under threat

AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

eGenesis tests gene

Agene-editedYucatanminipigcreatedbyeGenesis.CourtesyLizLinder/eGenesisForthreedaysinDecember,anICUro

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

Prior authorization will have to move faster under new Biden rule

AdobeTheBidenadministrationmovedWednesdaytoforceinsurancecompaniestogivespecificreasonsfordenyingcov